RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX)

Historical Holders from Q1 2019 to Q4 2025

Type / Class
Equity / Class A Common Stock, $0.00001 par value per share
Symbol
RXRX on Nasdaq
Shares outstanding
4,564,846
Price per share
$4.09
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
324,117,714
Total reported value
$1,581,601,631
% of total 13F portfolios
0%
Share change
+13,994,801
Value change
+$66,815,829
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
319
Price from insider filings
$4.36
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 8.5% $186,315,247 32,346,397 ARK Investment Management LLC 31 Dec 2024
BlackRock, Inc. 6.1% $134,995,023 23,436,636 BlackRock, Inc. 31 Dec 2024
RA CAPITAL MANAGEMENT, L.P. 2% $44,496,553 7,725,096 RA Capital Management, L.P. 31 Dec 2024
Kim Yohan 5.9% $1,540,800 267,500 Yohan Kim 04 Apr 2025
As of 30 Sep 2025, RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) has 319 institutional shareholders filing 13F forms. They hold 324,117,714 shares. .

Top 25 institutional shareholders own 6241% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 871% 39,780,153 +10% 0% $194,127,147
ARK Investment Management LLC 735% 33,545,499 +1.7% 0.97% $163,702,036
BlackRock, Inc. 695% 31,739,765 +12% 0% $154,890,053
BAILLIE GIFFORD & CO 525% 23,978,695 -0.81% 0.09% $117,016,031
STATE STREET CORP 400% 18,268,925 +63% 0% $89,152,354
SOFTBANK GROUP CORP. 321% 14,667,491 0% 0.28% $71,577,356
KINNEVIK AB (PUBL) 294% 13,434,171 0% 100% $65,558,755
Mubadala Investment Co PJSC 284% 12,985,927 0% 0.35% $63,371,324
MIC Capital Management UK LLP 211% 9,644,032 0% 9.4% $47,062,881
GEODE CAPITAL MANAGEMENT, LLC 211% 9,623,557 +24% 0% $46,971,473
NOVO HOLDINGS A/S 174% 7,929,835 -18% 2.5% $38,697,595
NVIDIA CORP 169% 7,706,363 0% 0.98% $37,607,051
Sumitomo Mitsui Trust Group, Inc. 164% 7,465,858 -8.6% 0.02% $36,433,387
Amova Asset Management Americas, Inc. 164% 7,465,858 -8.6% 0.35% $36,358,728
MORGAN STANLEY 160% 7,290,353 +28% 0% $35,576,930
Data Collective IV GP, LLC 130% 5,941,120 0% 43% $28,992,666
SUSQUEHANNA INTERNATIONAL GROUP, LLP 118% 5,389,176 +68% 0.04% $26,299,178
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 92% 4,196,978 -9.1% 0% $20,481,253
DCVC Opportunity Fund II GP, LLC 87% 3,951,141 0% 100% $19,281,568
UBS Group AG 82% 3,753,778 -19% 0% $18,318,437
Lingotto Investment Management LLP 81% 3,675,077 0% 0.34% $17,934,376
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 75% 3,445,020 +33% 0% $16,811,698
NORTHERN TRUST CORP 73% 3,337,296 +14% 0% $16,286,005
FMR LLC 71% 3,228,857 -42% 0% $15,756,823
TWO SIGMA INVESTMENTS, LP 54% 2,450,805 +110% 0.02% $11,959,928

Institutional Holders of RECURSION PHARMACEUTICALS, INC. - Class A Common Stock, $0.00001 par value per share (RXRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 410,727 $1,704,090 -$280,461 409% 12
2025 Q3 324,117,714 $1,581,601,631 +$66,815,829 488% 319
2025 Q2 310,183,849 $1,569,493,350 +$26,510,414 506% 330
2025 Q1 304,244,163 $1,609,644,574 -$29,277,151 529% 330
2024 Q4 304,503,855 $2,058,469,618 +$292,132,014 676% 310
2024 Q3 260,820,186 $1,719,746,530 +$28,653,319 659% 263
2024 Q2 251,850,622 $1,888,683,928 +$322,791,585 750% 266
2024 Q1 209,510,354 $2,088,608,377 +$37,886,806 997% 242
2023 Q4 115,242 $1,161,411 -$1,944,462 1,023.5% 2
2023 Q3 148,724,178 $1,137,621,261 +$183,957,032 765% 186
2023 Q2 124,630,128 $930,882,315 -$5,481,231 747% 152
2023 Q1 126,120,204 $841,172,158 +$14,956,626 667% 156
2022 Q4 123,700,274 $953,734,795 +$134,757,439 771% 142
2022 Q3 111,822,482 $1,189,744,484 +$75,116,009 1,064% 137
2022 Q2 103,476,748 $842,301,497 +$96,426,074 814% 127
2022 Q1 94,846,153 $678,702,525 -$13,110,736 715.98% 119
2021 Q4 93,345,592 $1,599,320,942 +$283,166,441 1,713% 120
2021 Q3 54,885,134 $1,262,502,377 +$181,282,325 2,300.99% 82
2021 Q2 46,974,230 $1,714,334,294 +$1,714,333,177 3,650% 77
2021 Q1 30 $1,000 $0 3,333.33% 1
2020 Q4 30 $1,000 $0 3,333.33% 1
2020 Q3 30 $1,000 $0 3,333.33% 1
2020 Q2 30 $1,000 $0 3,333.33% 1
2020 Q1 30 $1,000 $0 3,333.33% 1
2019 Q4 30 $1,000 $0 3,333.33% 1
2019 Q3 30 $1,000 $0 3,333.33% 1
2019 Q2 30 $1,000 $0 3,333.33% 1
2019 Q1 30 $1,000 $0 3,333.33% 1